The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Grimaldi, Anna ^a   Balestrieri, Maria Luisa ^a   D'Onofrio, Nunzia ^a   Di Domenico, Gilda ^b   Nocera, Cosimo ^b   Lamberti, Monica ^a   Tonini, Giuseppe ^c   Zoccoli, Alice ^c   Santini, Daniele ^c   Caraglia, Michele ^a   Pantano, Francesco ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Blood Transfusion Center   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CHLOROQUINE; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN KINASE B; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; MEMBRANE PROTEIN; RAPAMYCIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL COUNT; CELL FUNCTION; CELL GROWTH; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL PROGENITOR CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; STEM CELL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CHLOROQUINE; DRUG SYNERGISM; ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; SIROLIMUS; STEM CELLS;

EID: 84893158513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079658     Document Type: Article

References (63)

1. Masuda H, Asahara T (2013) Clonogenic assay of endothelial progenitor cells. Trends Cardiovasc Med. 23:99-103.
2. Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, et al. (2010) EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res. 79:207-216.
3. Yoder MC (2013) Endothelial progenitor cell: a blood cell by many other names may serve similar functions. J Mol Med. 91:285-295.
4. Bertolini F, Mancuso P, Benayoun L, Gingis-Velitski S, Shaked Y (2012) Evaluation of circulating endothelial precursor cells in cancer patients. Methods Mol Biol 904:165-72.
5. Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res. 79:224-228.
6. Schatteman GC, Dunnwald M, Jiao C (2007) Biology of bone marrow derived endothelial cell precursors. Am J Physiol Heart Circ Physiol 292:1-18.
7. Patenaude A, Parker J, Karsan A (2010) Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 79, 217-23.
8. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170:1-15.
9. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, et al. (2007) Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21:1546-1558. (Pubitemid 46955726)
10. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201. (Pubitemid 33063774)
11. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, et al. (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195-198.
12. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787. (Pubitemid 44454154)
13. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273.
14. Igreja C, Courinha M, Cachaço AS, Pereira T, Cabeçadas, et al. (2007) Characterization and clinical relevance of circulating and biopsyderived endothelial progenitor cells in lymphoma patients. Haematologica 92:469-477. (Pubitemid 350144292)
15. Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, et al. (2008) Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res. Treat. 107:133-138. (Pubitemid 350179580)
16. Keith CT, Schreiber SL (1995) PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270:50-1.
17. Schmelzle T, Hall MN (2000) mTOR, a central controller of cell growth. Cell 103:253-62.
18. Bjornsti MA, Houghton PJ (2004) The mTOR pathway: a target for cancer therapy. Nature Reviews Cancer 4:335-348. (Pubitemid 38579480)
19. Rossia M, Di Martino MT, Morellia E, Leotta M, Rizzo A, et al. (2012) Molecular Targets for the Treatment of Multiple Myeloma. Curr Cancer Drug Targets.12:757-767.
20. Yang Z, Klionsky DJ (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 22:124-131.
21. Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183:101-116.
22. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. (2010) Akt and autophagy cooperate to promote survival of drugresistant glioma. Sci Signal 3:ra81.
23. Xu CX, Zhao L, Yue P, Fang G, Tao H, et al. (2011) Augmentation of NVP-BEZ2359s anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12:549-555.
24. Agarwala S S, Case S (2010) Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15: 236-245.
25. Yim KL (2012) Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Management and Research 4:207-214.
26. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS. et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366: 520-529.
27. Curran MP (2012) Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Pediatric Drugs 14:51-60.
28. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, et al. (2011) Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3KmTOR pathway in pancreatic adenocarcinoma. J Mol Med 89:877-89.
29. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, et al. (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Research 66: 5549-554. (Pubitemid 43927103)
30. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 8:128-135. (Pubitemid 34155123)
31. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, et al. (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24:5414-5422. (Pubitemid 43080085)
32. Bergamini E, Cavallini G, Donati A, Gori Z (2003) The anti-ageing effects of caloric restriction may involve stimulation of macroautophagy and lysosomal degradation, and can be intensified pharmacologically. Biomedicine & Pharmacotherapy 57:203-208. (Pubitemid 36897686)
33. Meijer AJ, Codogno P (2004) Regulation and role of autophagy in mammalian cells. International Journal of Biochemistry & Cell Biology 36:2445-2462. (Pubitemid 39119758)
34. Mizushima N (2004) Methods for monitoring autophagy. International Journal of Biochemistry & Cell Biology 36:2491-2502.
35. Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmaco 625:220-33.
36. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, et al. (2010) Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10:370.
37. Fedele M, Franco R, Salvatore G, Paronetto MP, Barbagallo F, et al. (2008) PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. Journal of Pathology 215: 39-47. (Pubitemid 351619874)
38. Franco R, Boscia F, Gigantino V, Marra L, Esposito F, et al. (2011) GPR30 is over-expressed in post puberal testicular germ cell tumors. Cancer Biology and Therapy 11: 609-613.
39. Pattingre S, Levine B (2006) Bcl-2 inhibition of autophagy: a new route to cancer? Cancer Res 66:2885-2888.
40. Smolewski P (2006) Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17:487-494.
41. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
42. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618-631.
43. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, et al. (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814-8.
44. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95.
45. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, et al. (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139. (Pubitemid 46657433)
46. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147. (Pubitemid 38524883)
47. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, et al. (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94:524-533.
48. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835. (Pubitemid 37328901)
49. Ding YT, Kumar S, Yu DC (2008) The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 75:265-273.
50. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, et al. (2006) Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44:836-843. (Pubitemid 46489546)
51. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273.
52. Banerjee S, Xu H, Fuh E, Nguyen KT, Garcia JA, et al. (2012) Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosi 225:91-98.
53. Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, et al. (2006) mTOR inhibition induces endothelial progenitor cell death. Am J Transplant 6:2069-2079. (Pubitemid 44199541)
54. Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, et al. (2012) Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res 18:5278-5289.
55. Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25:6436-46. (Pubitemid 44582287)
56. Johnson BE, Jackman D, Janne PA (2007) Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 13:s4628-s4631.
57. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734. (Pubitemid 41486365)
58. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463-477. (Pubitemid 38456176)
59. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. (2004) The role of autophagy during the early neonatal starvation period. Nature 432:1032-1036. (Pubitemid 40052234)
60. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120: 237-248. (Pubitemid 40174766)
61. Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, et al. (2012) Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One 7:e41831.
62. Tertil M, Jozkowicz A, Dulak J (2010) Oxidative stress in tumor angiogenesis-therapeutic targets. Curr Pharm Des 16:3877-3894.
63. Pani G, Galeotti T, Chiarugi P (2010) Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29:351-378.